Ranbaxy’s Failure To Strike At Root Cause Triggered U.S. FDA’s Import Alert On Mohali Site

U.S. FDA identified several deviations in Ranbaxy’s Mohali oral dosage unit but was particularly concerned about the failure to identify the root cause for manufacturing deviations.